Observational analysis showed a correlation between MAN2A1 expression and TNBC malignancy, indicating potential therapeutic implications.
Background: This study investigated MAN2A1's role in regulating the proliferation, invasion, and migration of triple-negative breast cancer (TNBC) cells and its clinical significance. Methods: We enrolled 220 TNBC patients treated at our institution from January 2020 to December 2022. MAN2A1 protein expression was detected, and its correlation with TNBC clinicopathological features was analyzed. Western blot and immunohistochemistry measured MAN2A1 protein levels. CCK-8, colony formation, and EdU assays evaluated MAN2A1's impact on TNBC cell proliferation. Wound healing and Transwell assays assessed its effects on migration and invasion. Results: MAN2A1 protein expression positively correlated with TNBC malignancy. Functional assays demonstrated that MAN2A1 overexpression promoted TNBC cell growth, clonogenicity, migration, and invasion, while its knockdown suppressed these processes. Conclusion: As a key glycosylation enzyme, MAN2A1 is highly expressed in TNBC and positively correlates with malignancy. MAN2A1 overexpression acts as an oncogene by promoting TNBC progression, whereas its knockdown suppresses tumor growth, suggesting its potential as a therapeutic target to improve patient prognosis.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: